Background: Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%-50%) has been reported during pregnancy, but limited data on unbound exposure are available.
Introduction
Physiological changes during pregnancy can alter the pharmacokinetics of antiretroviral agents, mostly resulting in decreased antiretroviral exposure during pregnancy. 1 This may lead to virological breakthrough and/or development of antiretroviral resistance, as well as an increased risk of perinatal HIV transmission. 2, 3 To ensure effective ART, the impact of pregnancy on the pharmacokinetic properties of antiretroviral drugs must be considered.
Darunavir in combination with low-dose cobicistat (150 mg) should be explicitly avoided during pregnancy because of subtherapeutic exposure. 4 Darunavir in combination with low-dose ritonavir, however, can be used for treatment of HIV-positive pregnant women. 5 Lowered total darunavir exposure has been reported during pregnancy with decreases of AUC 0-s ranging from 17% to 50%. [6] [7] [8] [9] [10] To a lesser degree, lower unbound darunavir exposure has also been observed. 11 To maintain sufficient exposure, it has been recommended to use the standard twice-daily (q12h) 600/100 mg darunavir/ritonavir dosing regimen during pregnancy and not the standard once-daily (q24h) 800/100 mg regimen. 5, 12 However, it has also been argued that the standard dosing regimens are inadequate during pregnancy and an increased dose is needed. 13 The search for optimized darunavir/ritonavir dosing in HIVpositive pregnant women is complicated by several aspects of the darunavir/ritonavir pharmacokinetics. First, in plasma, darunavir is $94% protein bound, mainly to a-1-acid glycoprotein (AAG). During pregnancy, protein binding may be altered because of lower AAG plasma levels. 14, 15 This may result in decreased total darunavir exposure, but not necessarily in the unbound darunavir exposure (pharmacologically active), as observed previously for darunavir in pregnancy. 9 Moreover, it has been reported that darunavir protein binding is non-linear in its therapeutic range. 16 Secondly, darunavir biotransformation is almost exclusively mediated by cytochrome P450 (CYP) 3A4 and darunavir is a substrate for P-glycoprotein (P-gp). 17 It has been suggested that both the CYP3A4 and P-gp activities are altered during pregnancy. 15 This may lead to changes in darunavir pharmacokinetics.
Furthermore, in clinical practice, ritonavir co-administration is essential to reduce darunavir clearance, increase darunavir bioavailability, reduce pill burden and maintain adequate plasma concentrations throughout the dosing interval. 18 This is commonly referred to as pharmacokinetic boosting. Ritonavir is a potent CYP3A4 inhibitor and reduces darunavir clearance, leading to higher plasma concentrations throughout the dosing interval. 18 Ritonavir is also known to have potent inhibitory effects on the efflux drug transporter (P-gp), which, in the intestine, may also contribute to the increased darunavir bioavailability and hence exposure. 17 Ritonavir biotransformation is also mediated by CYP3A4. Changes in ritonavir exposure, resulting from pregnancy-induced CYP3A4 activity, may result in altered darunavir CYP3A4/P-gp inhibition during pregnancy compared with non-pregnant women. 9 Failure to take these pharmacokinetic aspects into account could result in (proposed) suboptimal dosing regimens in pregnant women with respect to exposure and hence treatment outcomes.
To investigate further the adequacy of standard darunavir/ritonavir dosing in pregnancy we performed a semi-mechanistic population pharmacokinetic analysis of the pharmacokinetics of darunavir and ritonavir in pregnant women. Ultimately, the developed model was used to evaluate total and unbound darunavir exposures following standard darunavir/ritonavir dosing, but also to explore the value of potential optimized dosing regimens for HIV-positive pregnant women.
Methods

Pharmacokinetic data
Data from two studies that included pregnant women taking darunavir/ritonavir were pooled. Study details have been reported previously. 9, 10 Both studies had a similar observational design. Women had intensive pharmacokinetic assessments during pregnancy (second and/or third trimester) and post-partum. The post-partum visit served as the control for the nonpregnant situation. In total, 2265 plasma concentrations were available from 85 women, of which 1431 plasma concentrations were during pregnancy. Corresponding unbound darunavir concentrations were determined in 74 plasma samples from 20 women, during pregnancy and postpartum. Further details and demographics are provided in Table 1 .
The number of darunavir plasma samples below the lower limit of quantification (BLQ) was small (,1%) and excluded. For ritonavir the number of plasma samples BLQ was substantial ($15%; Table 1 ) and the M3 method 19 was used to deal with BLQ data. With this method the likelihood of being BLQ is incorporated into the model. In both studies, validated (ultra) HPLC assays were used. 9, 10 Population pharmacokinetics
Several population pharmacokinetic models for darunavir/ritonavir in a non-pregnant population are available in the literature. These models are largely empirical and hence not able to deal with the complicating pharmacokinetic processes specified in the Introduction section and not based on data from pregnant women. 14, 20 Nevertheless, these models formed the background for further darunavir/ritonavir model development in pregnant women. The final model was developed in three steps. First, the darunavir protein (AAG)-binding dissociation constant (K d ) and the maximal protein binding capacity (B max ) were estimated based on non-linear mixed-effects analysis of a subset of paired samples of total and unbound darunavir concentrations in pregnancy and post-partum. Then, separate population pharmacokinetic models were developed for ritonavir and darunavir. The darunavir K d and B max estimated from the previous step were used and fixed in the darunavir model. Thereafter, the darunavir-ritonavir interaction was simultaneously modelled based on the darunavir and ritonavir data in pregnancy and post-partum. Pregnancy and gestational age were tested as covariate on all ritonavir and darunavir model parameters. Model development in each step is further detailed in Supplementary data S1 (available at JAC Online).
Model evaluation and qualification
Throughout the model building process, we evaluated precision in parameter estimates obtained by the covariance step ($COV) and standard goodness-of-fit plots. For the final models, parameter uncertainty was calculated with the sampling importance resampling (SIR) procedure. 21 To qualify the final model for simulation we evaluated prediction-corrected visual predictive checks (pcVPCs) and goodness-of-fit plots. 22 
Simulation
For simulation we focused on the third trimester of pregnancy, rather than earlier phases of pregnancy, since the risks of mother-to-child transmission are highest during late pregnancy and labour and the potential changes in pharmacokinetics are presumed to be at their peak. 5 The final darunavir/ritonavir model was used to simulate relevant secondary pharmacokinetic parameters (AUC 0-s and C trough ) following standard and alternative q24h and q12h darunavir dosing in typical pregnant (at 38 weeks of gestation) and non-pregnant (i.e. post-partum) women. For exploration of higher ritonavir doses (i.e. increased boosting), linear pharmacokinetics were assumed for ritonavir up to 200 mg q12h, at steady-state. 23, 24 In addition, the probability of therapeutic exposure was assessed. The target for darunavir was set to the protein-adjusted EC 50 for resistant virus: 0.55 mg/L. 16 The SimCYP simulator was employed to create a dataset with demographics [fat free mass (FFM) and total bodyweight (TBW)] for 5000 virtual pregnant (38 weeks of gestation) and non-pregnant (0 weeks of gestation) women using correlated Monte Carlo sampling. This dataset was used to simulate C trough for the different dosing regimens and, subsequently, assess the probability of therapeutic exposure.
Additionally, we explored simulated unbound darunavir AUC 0-s and C trough . This was based on the predicted (concentration-dependent) f u predicated on pregnancy status and the model-simulated total darunavir plasma concentration (C tot ), using:
The probability of therapeutic exposure was also assessed for unbound C trough . For this purpose, the target was set to 0.0275 mg/L; the Darunavir/ritonavir dosing in pregnancy JAC unbound EC 50 assuming 95% protein binding in typical non-pregnant adults.
Software
Data were analysed using NONMEM V R 7.4.1 (ICON Development Solutions, Hanover, MD, USA). The first-order conditional estimation method was used. Pirana 2.9.1 (http://www.pirana-software.com) was used as an interface for NONMEM to structure and document model development. 25 R version 3.4.2 (with Rstudio interface version 1.1.383) was used for data preparation, exploratory analyses, and graphical visualization and evaluation. Perl Speaks Nonmem 4.6.0 was used for automation of a diverse range of processes related to non-linear mixedeffects model development. 26 SimCYP V15 Simulator was used to obtain demographic datasets for simulation.
Results
Darunavir protein binding
The unbound darunavir concentrations ranged from 0.04 to 1.35 mg/L and the paired total concentration ranged from 0.32 to 9.2 mg/L. Inclusion of pregnancy as a dichotomous covariate for B max significantly improved the model fit [change in objective function value (DOFV) #22.1; P , 0.01]. The parameter estimates for the darunavir protein binding model are listed in Table 2 . These results are in line with data on darunavir protein binding in healthy volunteers presented in the registration package ( Figure 1 ). 16 The parameter uncertainties in B max and K d were highly correlated (83%). Goodness-of-fit plots and pcVPCs are included in Supplementary data S2. Schalkwijk et al.
Darunavir and ritonavir population pharmacokinetic analyses
The observed ritonavir concentrations ranged from ,0.045 (lower limit of quantification) to 0.9 mg/L. A one-compartment disposition model with sequential zero-and first-order absorption and first-order elimination best described the data. Inter-individual variability was included for clearance (CL/F; F was fixed to 1) and central volume of distribution (V c /F) with the covariance term estimated for CL/F and V c /F (DOFV #15.4). Inter-occasion variability was included for F (systemic bioavailability; DOFV #318.9). The residual error structure was proportional. Fixed allometric scaling with TBW for volume of distribution and clearance best described the data (total DOFV #13.8). Standard stepwise covariate modelling led to the inclusion of linear parameter-gestational age relationships for F (DOFV #25.4; P , 0.01). Population estimates are shown in Table 3 . Goodness-of-fit plots and pcVPCs (continuous and censored for BLQ 19 ) are included in Supplementary data S3. The observed total darunavir concentrations ranged from 0.1 to 18.5 mg/L. In addition to the well-stirred liver model, a twocompartment disposition model and absorption through one absorption transit compartment best described the data. Inclusion of the parameters B max (predicated on pregnancy status) and K d to describe the relation between f u , and hence plasma clearance (CL hep /F), and total darunavir concentrations improved the model fit (DOFV of #61.0). Inter-individual variability was included for V c / F (total DOFV #299.5). Inter-occasion variability was included for CL int /F (DOFV #195.1). The residual error structure was proportional. Body size scaling did not significantly improve the model fit. FFM was used for parameters related to the liver and central compartment, and TBW was used for scaling of the parameters related to the peripheral compartments. Stepwise covariate modelling did not lead to further inclusion of parameter-pregnancy relationships for darunavir pharmacokinetics in the simultaneous fit.
Darunavir-ritonavir interaction model
For darunavir, a direct proportional relationship between ritonavir and darunavir clearance improved the model fit as expected Table 2 . Darunavir/ritonavir dosing in pregnancy JAC (DOFV #78.4). The maximum-inhibition model further improved the model fit (2df; DOFV #16.4; P , 0.01). Population estimates are shown in Table 3 . Goodness-of-fit plots and pcVPCs are included in Supplementary data S4. Several stratifications of the pcVPCs were evaluated, including study (study 1 versus study 2), but no misspecifications were observed (data not shown). The final model used for simulation is graphically represented in Figure 2 .
Simulation
Relevant exposure parameters and probabilities of therapeutic exposure for standard darunavir/ritonavir dosing regimens are listed in Table 4 . In the third trimester of pregnancy total darunavir exposure (AUC 0-s ) was reduced by 24% and 23% compared with post-partum for darunavir/ritonavir 800/100 mg q24h and 600/ 100 mg q12h, respectively. Total darunavir C trough in the third trimester of pregnancy was reduced by 31% and 28% compared with post-partum for darunavir/ritonavir 800/100 mg q24h and 600/100 mg q12h, respectively. For darunavir, unbound pharmacokinetic parameters were also explored based on predicted f u. In the third trimester of pregnancy unbound darunavir AUC 0-s was reduced by 5% and 8% compared with post-partum for darunavir/ ritonavir 800/100 mg q24h and 600/100 mg q12h, respectively. Unbound darunavir C trough in the third trimester of pregnancy was reduced by 14% and 11% compared with post-partum for darunavir/ritonavir 800/100 mg q24h and 600/100 mg q12h, respectively. The probability of therapeutic exposure for darunavir/ ritonavir 600/100 mg q12h was .95% based on the total and unbound target concentrations, irrespective of pregnancy status. The probability of therapeutic exposure following darunavir/ritonavir 800/100 mg q24h in pregnancy was 78% based on the total target concentration. The probability of therapeutic exposure for darunavir/ritonavir 800/100 mg q24h in pregnancy based on the unbound target concentration was higher (94%; Table 4 ). Nevertheless, the latter indicates that still 1 of $17 pregnant women will have subtherapeutic unbound exposure, compared with 1 of $33 non-pregnant women. Several strategies were explored to increase darunavir exposure during pregnancy, including higher ritonavir dosing (i.e. more boosting) and/or higher darunavir dosing. The impact of higher ritonavir dosing on darunavir AUC 0-s and C trough was minor (Table 4) . Additionally, the probability of therapeutic exposure following darunavir/ritonavir 800/200 mg q24h in the third trimester of pregnancy did not increase to the probability of therapeutic exposure for the standard 600/100 mg q12h dosing in pregnancy. For darunavir/ritonavir 600/200 mg q12h, increments in AUC 0-s , C trough and probability of therapeutic exposure were minor and insignificant when compared with darunavir/ritonavir 600/100 mg q12h.
As highlighted in the Introduction section, higher darunavir q12h dosing has been proposed for pregnant women. In Figure 3 the simulated typical exposure for pregnant and non-pregnant women is plotted as a function of different darunavir q12h doses with standard 100 mg ritonavir boosting. As expected, a non-linear relationship between dose and total darunavir exposure was observed. This can be distinguished from a linear relationship between dose and unbound darunavir exposure (predictions not shown). The probability of therapeutic exposure for darunavir/ritonavir 1200/100 mg increased, but was still lower than with standard 600/100 mg q12h dosing (Table 4) . Darunavir/ritonavir 800/100 mg q12h further increased darunavir AUC 0-12 and C trough in pregnancy compared with the standard dosing regimens in pregnancy, yet the gains in probability of therapeutic exposure were minor and not relevant (Table 4) .
Discussion
In this semi-mechanistic population pharmacokinetic analysis, darunavir exposure following the standard darunavir/ritonavir dosing regimens was reduced in the third trimester of pregnancy compared with non-pregnant women. Total darunavir exposure (AUC 0-s ) was reduced by 24% and 23% during the end of the third trimester compared with post-partum for darunavir/ritonavir 800/ 100 mg q24h and 600/100 mg q12h, respectively. This was in line with results from previous studies that showed reductions in total darunavir plasma concentrations of between 20% and 50% during the third trimester of pregnancy. [6] [7] [8] [9] [10] Table 4 . Simulated typical darunavir pharmacokinetic parameters and probability of therapeutic exposure for standard and doubled ritonavir boosting GA, gestational age; C trough , concentrations at the end of the dosing interval; TA, therapeutic exposure; t, total; u, unbound. Darunavir/ritonavir dosing in pregnancy
JAC
The clinical relevance of these pregnancy-induced alterations in exposure is under debate. Often exposures are assessed by means of bioequivalence boundaries, often 80%-125%. For darunavir exposure in pregnant women, this criterion was not met in the present analysis. This was consistent with findings from previous studies. However, results from in vitro studies demonstrate alterations in antiviral activity resulting from changes in darunavir protein binding. 27 In vivo, non-linearities and pregnancy-induced changes in darunavir protein binding could therefore result in shifts in apparent antiviral activity. Under such conditions, unbound plasma concentrations are a better proxy for the pharmacologically active concentration at the site of action. 28 Evaluating the simulated unbound darunavir AUC 0-s , reductions were much smaller (5%-8%) and the bioequivalence criterion was met for both standard q24h and q12h dosing. This was in line with the results from a previous study.
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Exposure in pregnancy can also be examined relative to therapeutic targets. Preferably, therapeutic targets are set based on exposure-response relationships from clinical data, but these were not available for darunavir (in pregnant women). The longstanding and widely used (in therapeutic drug monitoring) darunavir therapeutic target of 0.55 mg/L is translated from in vitro to in vivo potency (i.e. protein-binding adjusted) and 10 times higher than the EC 50 for the least susceptible multi-PI-resistant HIV-1 strains isolated from patients. 27 This target is therefore considered relatively conservative. The probability of therapeutic exposure following darunavir/ritonavir 800/100 mg q24h in pregnancy, however, was 78% based on the total target concentration. This indicates subtherapeutic exposure for 1 in 5 pregnant women. Nevertheless, for reasons outlined above, unbound therapeutic targets seem more appropriate to examine darunavir exposure in pregnancy. Assuming 95% protein binding in typical non-pregnant women the unbound target was set to 0.0275 mg/L (5% of the 0.55 mg/L target). The probability of therapeutic exposure for darunavir/ritonavir 800/100 mg q24h in pregnancy based on the unbound target was higher (94%), but indicated that still 1 of $17 pregnant women will have subtherapeutic unbound exposure, compared with 1 of $33 non-pregnant women. This could be explained by lower ritonavir exposures in pregnant women and thus less inhibition.
Alternative darunavir/ritonavir dosing regimens were also explored. Higher ritonavir (i.e. more boosting) or darunavir dosing increased the probability of therapeutic exposure for darunavir q24h dosing in pregnancy. These strategies may provide an occasional solution for pregnant women that should in fact be on a q12h regimen, but that are for some reason bound to q24h dosing. Such strategies can be considered combined with therapeutic drug monitoring. The results of the current study do not necessarily warrant higher ritonavir or darunavir dosing. It should be noted that increments in total exposure were not proportional to dose and thus less than expected based on linear darunavir pharmacokinetics. This was, in fact, observed in a preliminary analysis of data on darunavir/ ritonavir 800/100 mg pharmacokinetics in pregnancy. 13 The pharmacokinetic models developed in the current study were consistent with previously developed models for darunavir and ritonavir, in terms of compartmental structure and parameter estimates. 14, 20 In contrast to previous work, however, the present analysis used a well-stirred liver model for darunavir and focused on the impact of pregnancy on the pharmacokinetics. Gestational age (i.e. pregnancy) was found to reduce ritonavir relative bioavailability. This is most likely explained by pregnancy-induced alterations in CYP3A4 and/or P-gp activity. 29 In this analysis the post-partum assessments served as the control for the nonpregnant situation (i.e. gestational age 0) and it can be questioned to what extent pregnancy-induced physiological processes (e.g. enzyme expression or protein levels) have normalized during the early post-partum period. Fortunately, in the current study, post-partum samples were mostly taken at least 4-6 weeks after delivery and previous work 30 indicated that this time span is sufficient for relevant physiological processes to normalize, supporting our approach. Schalkwijk et al.
Another important aspect of our analysis was the interaction between ritonavir and darunavir. Separating ritonavir-mediated inhibition from the inherent correlation between pharmacokinetics of both compounds is cumbersome, though essential. Here, this was handled in a pragmatic way supported by mechanistic reasoning and information. In the absence of enzyme saturation (i.e. linear biotransformation), darunavir and ritonavir clearance are directly proportional to enzyme abundance. Consequently, a directly proportional relation between ritonavir clearance and darunavir clearance was assumed. Although this assumption is arguable, it is a reasonable approximation of the inherent relation between ritonavir and darunavir pharmacokinetics and particularly more reasonable than no relation at all. Subsequently, the ritonavir concentrationdependent inhibition of darunavir clearance was estimated and the identified IC 50 was in line with those previously reported for ritonavir inhibition of darunavir, 14 but also lopinavir. 31 Maximum inhibition was estimated to be $35%. Fixing the maximum inhibition to 100% or testing complete competitive inhibition described the data less well. This was clearly reflected in the data where darunavir clearance did not further decrease with high versus higher ritonavir exposures. This indicates that ritonavir is not able to inhibit completely the darunavir clearance. This may be related to known un-or noncompetitive elements to ritonavir inhibition, but also to other pathways for darunavir biotransformation or elimination. 32, 33 Notably, the ritonavir concentrations observed clinically are mostly well above the IC 50 and inhibition is maximal. Only few subjects with concentrations at the lower end of the distributions (particularly in pregnancy) will have submaximal inhibition.
A strength of this study was its semi-mechanistic nature. The mechanistic aspects of the darunavir model allowed us to distinguish between changes in total darunavir exposure resulting from changes in protein binding from those resulting from pregnancyinduced intrinsic clearance or ritonavir-mediated inhibition of intrinsic clearance. This, in turn, allowed us to distinguish between pregnancy-related changes in total and unbound darunavir concentrations in the simulations, which provided relevant insight for exploring darunavir/ritonavir dosing regimens in HIV-positive pregnant women. Ritonavir was modelled in a more empirical manner and mostly relevant as input to the darunavir model. Although it could be argued that the darunavir-ritonavir interaction should be modelled based on unbound ritonavir concentrations, ritonavir protein binding is linear over the clinical concentration range and pregnancy-induced alterations in plasma binding were found to be minor. 34 We therefore think total ritonavir concentrations were a good (enough) proxy to model the direct ritonavir-mediated inhibition of darunavir clearance.
A limitation to the current study was that only small numbers of matched total and unbound concentrations were available. Yet, estimating the binding parameters from the subset of matched total and unbound darunavir concentrations allowed inclusion of non-linear protein binding in the final model. The estimated B max was largely in line with the B max in plasma from healthy volunteers (Figure 1) . The minor differences in B max observed are consistent with reported differences in fraction unbound for healthy volunteers 16 and HIV-infected (pregnant) women. 9 The effect of pregnancy on B max (22% decrease) was in line with the overall average change in AAG concentrations during (the third trimester of) pregnancy found in the literature (15% decrease 35 ), which is expected to be directly proportional to B max . It should be noted that the B max estimate (but also other estimates) was based on data from the third trimester. Therefore, extrapolations to the first and second trimesters based on this model may not be valid. Additionally, simulation in the current study did not take parameter uncertainty into account.
Overall, the standard darunavir/ritonavir 600/100 mg q12h regimen resulted in maximal rates of therapeutic exposure in pregnancy and was quantitatively superior to 800/100 mg q24h in pregnancy, based on total and unbound darunavir exposure (AUC 0-s and C trough ) and probability of therapeutic exposure. It has been argued to limit the use of darunavir/ritonavir 800/100 mg q24h to antiretroviral-naive pregnant women for whom PI mutations can be excluded. For these women, lower target concentrations have been proposed (0.2 mg/L). 11 In addition, in case of good adherence and therapeutic drug monitoring, q24h dosing can be considered. In all other cases though, our analysis indeed suggests that darunavir/ritonavir 600/100 mg q12h should be the regimen of preference during pregnancy.
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